Stroke Drug Trial Reaches Enrollment Milestone
The 200-patient milestone triggers an interim analysis to determine the future path of this stroke study.
Updated on Oct. 22, 2026 in Stroke
Live Poll
Do you trust pharmaceutical trials that adjust their sample size after they have already begun?
DiaMedica Therapeutics has reached a 200-patient enrollment milestone for its ReMEDy2 clinical trial evaluating the investigational drug DM199 for acute ischemic stroke. This interim data will now undergo an independent review to determine if the study should continue or adjust its final sample size.
Why it matters
This analysis is critical for determining the study's trajectory, as it balances the need for statistical power against the objective of efficiently testing a potential new treatment. Adjusting sample sizes based on early findings ensures researchers can accurately measure efficacy for patients ineligible for traditional mechanical thrombectomy.
The ReMEDy2 trial is a multi-site study assessing the efficacy of DM199 compared to a placebo in patients who have experienced an acute ischemic stroke but have not undergone mechanical thrombectomy. The interim analysis will evaluate results from the first 200 participants to inform the final study size.
The players
DiaMedica Therapeutics
A clinical-stage biopharmaceutical company focused on developing novel treatments for kidney and neurological diseases.
Data Safety Monitoring Board
An independent committee of experts responsible for reviewing clinical trial data to ensure participant safety and study integrity.
The details
DM199 is being tested as a potential treatment to improve outcomes for patients following an acute ischemic stroke. In the trial, participants receive either the drug or a placebo over a three-week period, followed by a 90-day observation window to measure recovery. The primary endpoint for success is defined as achieving a modified Rankin Score of 0 or 1 at Day 90, indicating a high level of functional independence.
Timeline
Q1 2027: Expected completion date for the interim analysis.
Health Landscape
Stroke treatment options are currently dominated by mechanical thrombectomy for large vessel occlusions, leaving a significant gap for patients who do not qualify for that procedure. The ReMEDy2 clinical trial represents a targeted effort to find pharmacological alternatives that can improve patient recovery trajectories.
This development is part of an ongoing clinical study and does not change current standard-of-care stroke treatments. Patients and their families should discuss any questions regarding stroke recovery options and enrollment in clinical research with their primary neurologist.
The takeaway
This trial milestone highlights the rigorous, multi-stage process required to evaluate new stroke interventions before they can be considered for clinical use. Patients interested in how research trials function can follow updates from the National Institutes of Health regarding clinical trial phases and patient safety.
What happens next
The independent Data Safety Monitoring Board will complete its interim analysis of trial data in the first quarter of 2027.
Further reading
Learn more about the latest research and clinical developments in our Stroke section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust pharmaceutical trials that adjust their sample size after they have already begun?
